Author

Sophie Biguenet 1

1 Abivax, Paris, France

ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Severine Vermeire, Bruce E. Sands, Sophie Biguenet, Hartmut Ehrlich, Paul GINESTE, Josianne Nitcheu, William J. Sandborn

ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS

Severine Vermeire, William J. Sandborn, Herbert Tilg, Paul GINESTE, Radoslaw Kempinski, Zsolt Tulassay, Josianne Nitcheu, Sophie Biguenet, Hartmut Ehrlich, Jean-Marc Steens, Bruce E. Sands, Silvio Danese

Item 1 - 2 / 2
1